FAP-targeted PET/NIR in Lung Malignant Tumors

01 Apr 20264 min read0 viewsOBSERVATIONAL Trial

GIST (Key Takeaways)

RECRUITING · OBSERVATIONAL · Non-Small Cell Lung Cancer · Enrollment 200 · Sponsor: Peking University People's Hospital

Clinical Editorial

ClinicalTrials.gov published a clinical update in Oncology on 01 Apr 2026. The item focuses on FAP-targeted PET/NIR in Lung Malignant Tumors. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT07498933

Open Original Source More Feed Items

Related by Condition/Drug

Refining Neoadjuvant And Perioperative Therapy In Nsclc

Oncology • 30 Jun 2026

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Oncology • 21 Apr 2026

ClinicalTrialsRelated by Conditionlung cancer

Pilot Study of Spatially Fractionated Radiation Therapy in Extra-Cranial Soft Tissue Metastases

Oncology • 30 Mar 2026

ClinicalTrialsRelated by Conditionlung cancer

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Oncology • 06 Feb 2026

Prognostic significance of extracapsular extension in patients with non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a retrospective cohort study

Infectious Disease • 15 Jul 2026

From associations to clinical practice: translating inflammatory-nutritional indices into a machine learning-driven model for breast cancer risk stratification with cross-ethnic validation

Infectious Disease • 15 Jul 2026

Feed Metadata

Source

ClinicalTrials.gov